Rationale, aims, and objectives: Medication-related problems are frequent and can lead to serious adverse events resulting in increased morbidity, mortality, and costs.
| INTRODUCTION
Medication-related problems such as medication errors, inappropriate prescribing, and compliance problems are frequent 1, 2 and can lead to serious adverse events resulting in increased morbidity, mortality, and costs. [3] [4] [5] [6] [7] It is estimated that 2% to 30% of all hospital admissions are medication related 2, [8] [9] [10] and that up to 10% of all medicationrelated adverse events could be life-threatening or fatal. 11 In a Swedish study, these adverse events caused almost 10% of all direct health care costs in the study population. 12 Medication use in frail older patients is even more complex because of factors such as age-related changes in body composition, use of more medications with increasing age, 13 and as this patient group often suffers from multiple morbidities. 14 Therefore, the risk of adverse events related to medication increases with increasing patient frailty. 15 Two meta-analyses demonstrated that about half of the medication-related adverse events might be prevented, especially among the older. 3, 4 In many hospitals, clinical pharmacists identify and solve medication-related problems during medicines management as an attempt to prevent medication-related adverse events. This practice has evolved over the last few decades but is in Denmark not yet offered throughout the country, and the procedure and elements such as medication history, medication reconciliation, medication review, and patient counselling often vary from ward to ward. 16 Recent systematic reviews on medicines management in hospitals [17] [18] [19] have shown a tendency towards improvement in medication use, health service use, and costs, but the evidence is not consistent.
More research is therefore needed both on the effect of medicines management for older inpatients and on the different parts of medicines management.
Hence, the aim of this study was to investigate the effect of a pharmacist-led medicines management model among older patients at admission, during inpatient stay, and at discharge on medicationrelated readmissions.
2 | METHODS
| Study design and setting
This was a randomized controlled study, where older patients aged 65 years or above were randomized to either a control group or one of two groups receiving pharmacist-led interventions.
Patients were included from the medical acute admission unit at Hospital South West Jutland. A ward-based pharmacist had not previously been available here. Upon admission, a nurse met the patient and graded the severity of the illness in a Triage system ranging from 1 (extremely ill) to 5 (not acutely ill). Within half an hour after admission, patients were examined by a senior physician, including decisions about treatment level, and within 4 hours a junior physician examined the patient, and a treatment plan was agreed on. Patients were transferred to a specialized department if their inpatient stay was expected to exceed 48 hours. The remaining patients stayed on the acute admission unit until their discharge. 20 The hospital introduced electronic patient records in March 2013. it was an online system with an overview of all prescriptions for the last 2 years. Hereafter, the FMK system was integrated into the electronic patient records as a list of the current medication used by the patient. As this new feature is not fully validated yet, the physicians still combine information from the system with patient interview to obtain the medication history.
| Study participants
A pharmacist was present Monday to Friday between 7:30 am and 5 pm. Every day, the pharmacist screened patients admitted to the ward for inclusion. Patients could be included if they were 65 years of age or above, acutely admitted, medical patients (not surgical), able to give informed consent, able to speak and understand Danish, and holding a Danish personal registration number. Patient were excluded if they were extremely ill (ie, Triage 1), terminal, had not been seen by either a nurse or physician yet, were not accessible, or had previously been included in the study.
The patients were randomized using a 1:1:1 allocation ratio to one of three groups in blocks of 15 (each block contained five patients from each group) using the opaque closed envelope technique. The randomization process was performed at Odense University Hospital.
The patients were included consecutively. The pharmacist opened the envelope at the bedside after patient consent was obtained, and the patient was informed immediately about allocation. The group allocation was not blinded to the patient, the pharmacist, or other health care professionals present at the ward.
| The interventions
The three groups consisted of a control group named Control (usual care) and two intervention groups named ED (basic intervention) and STAY (extended intervention). All patients received usual care including medication history, medication reconciliation, and medication review by a physician without any structured instrument as part of the normal procedure. The Control group was not offered any pharmacist-led intervention. Both the ED group and the STAY group received a pharmacist-led medication review (including patient interview and medication reconciliation) on admission. Furthermore, patients in the STAY group transferred to a specialized ward received a medication review during inpatient stay together with patient counselling and a medication report at discharge. All pharmacist-led interventions during the study were performed by the same pharmacist, who had 3 years of clinical experience.
| Medication review and patient interview
The medication review on admission followed a systematic procedure previously described in detail. 22 Briefly, the procedure consisted of five steps. First, patient data were collected from the electronic patient record. Secondly, information about the patients' medical treatment and medication history was collected from the patient record and FMK, if available. Next, an interview with the patient was conducted at the bedside in order to collect information about the patients' use of medicines, and to identify whether the patient had experienced medication-related problems. Next, a critical examination of the patient's medical treatment focusing on the entire treatment (including medication reconciliation) and on every single medication was conducted by the pharmacist. Recommendations about changing regimens for economic reason were only conducted if it would affect the patient. Finally, the recommendations for medical changes were reported to the physician electronically in the patient record and supplemented with dialogue with the physician whenever possible. The second medication review for patients in the STAY group followed the same procedure, but medication history and patient interview was omitted, because this had been performed for all intervention patients upon admission.
| Medication report at discharge
The medication report created for the patients' discharge consisted of a note in the electronical medical record where the pharmacist listed all changes to the patient's medication use during inpatient stay. Reasons for change and further recommendations to the patient's general practitioner were also listed. The medication report was only used as a reminder to the physician at discharge, who could choose to mention the content of the medication report in the electronic discharge summary to the general practitioner.
| Patient counselling at discharge
At discharge, the patients in the STAY group were offered counselling on their medical treatment. The counselling should identify if the patient were given a new list of medications to use after discharge, and if they had any questions about changes in the medications or to the treatment in general.
| Pilot study
A pilot study consisting of a feasibility test was performed. The test included nine patients with testing of the data collection forms and logistics of the study. None of the pilot study patients was included in the results.
| Data collection and analysis

| Patient characteristics
Patient characteristics were collected from the patient record. The same source of information was used for all study patients, even if more information was available for intervention patients after the patient interview.
| Process data
Process data recorded during the study period included time spent on each part of the intervention, the number of medication-related problem identified, and the physicians' acceptance of the recommendations. The medication-related problems were scored using The PCNE Classification V 6.2 23 
modified with two new categories Medication
Reconciliation and Technical Error (see Appendix 1).
All data on patient characteristics and process data were entered directly into EpiData EntryClient (version 1.3.1.1, EpiData Association, Denmark).
| Outcome data
The primary outcome was number of patients with a medicationrelated readmission within 30 days from discharge. Data about all readmissions were collected from the Danish National Patient Registry, 24 and for the first unplanned readmission within 30 days, the pharmacist extracted data from the patient record with all clinical notes, a medication list, and laboratory results from the first days of the readmission. It was ensured that the intervention was not mentioned in the extracted data. Two researchers, with expertise in clinical pharmacology and geriatrics, individually conducted the analysis of the primary outcome. Information about group allocation was blinded to these researchers. The assessment of whether a readmission was medication-related or not followed a strict procedure based on WHO-UCM international agreed criteria for causality and Hallas' criteria for contribution. 25, 26 Any discrepancies in the assessment were resolved and consensus obtained. The selected timeframe for readmission was based on a review where the majority of studies have defined readmissions as within 30 days from discharge. 27 Secondary outcomes included mortality (overall, during index admission, within 30 days after discharge or 31-180 days after discharge), patients with readmissions (acute and planned, both including medication-related readmissions) within 30 days after discharge, and number of visits to the emergency department, the hospital, or a general practitioner within 180 days after discharge. These data were collected from the nationwide registers from the Danish Health Authorities: the Civil Registration System, 28 the National Health Insurance Service Registry, and the National Patient Registry. 24 
| Sample size and statistical methods
Estimation of sample size was based on results from two Swedish studies 29, 30 in which the frequency of medication-related readmissions was reduced from 24% to 4.9% and from 12% to 5.6%, respectively. The sample size was based on comparison between the Control and ED groups, as it was assumed, that nearly half of the patients in the STAY group would be discharged directly from the acute admissions unit and therefore not eligible to receive the interventions during stay and at discharge. For this reason, the analysis of the STAY group was mostly explorative.
Based on a readmission frequency similar to the largest study (24%), 176 patients had to be enrolled in each group to detect a reduction as in the most conservative study (50%) with 80% power. To compensate for drop-out, the number was increased to 200 patients in each of the three groups.
All analyses were performed using Stata v. 
| Patient data
In Table 1 , patient characteristics at baseline for the three groups can be seen. The median age for all patients was 74 years and 51% were males. The mean age for the patients in the Control, ED, and STAY groups was 75.9, 74.8, and 75.4 years, respectively. The groups were well balanced in all aspects.
| Process data
In Figure 1 is the number of patients actually received the interventions shown. Details of the interventions are shown in Table 2 .
At admission, the pharmacist identified 1138 medication-related problems. For 243 problems, no recommendations for change was suggested as the physician was only informed, and 67 problems were not relevant to solve after all (eg, due to problem not present anymore). Hence, the pharmacist recommended 828 changes in medication. During inpatient stay and at discharge, additional 145
medication-related problems and 92 recommendations for change were identified. For 38 problems, the physician was only informed, and 15 problems were not relevant to solve after all.
For the 920 recommendations for medication change, the main causes of the medication-related problem were medication selection (n = 424, 46%), medication reconciliation (n = 239, 26%), and dose selection (n = 117, 13%). The overall acceptance rate was 57%
(accepted by the physician), 3% was rejected by the physician, and 40% was unknown (no evaluation or action from the physician neither orally or written in the record). See Appendix 1 for the PCNE classification of all the recommendations.
3.4 | Outcome data
| Medication-related readmissions (primary outcome)
A total of nine patients were excluded from the analysis of the primary outcome (seven patients died during inpatient stay and two patients died during 30-day follow up). Four patients had an acute readmission before they died within 30 days and they were hence included in the analysis (see Figure 1 ).
Eleven Control patients, nine ED patients, and five STAY patients had a medication-related readmission, with no statistical significant difference between the groups (see Table 3 ). The reasons for readmission were side effects (n = 11, 44%), therapeutic failure (n = 8, 32%), and untreated indication (n = 6, 24%). Of the medication-related readmissions, 10 (40%) were assessed as preventable, 13 (52%) as non-preventable, and 2 cases had not enough data to be assessed.
Most of the medication-related readmissions had a possible causality with medications partly contributing to the readmission (n = 14, 56%).
| Secondary outcomes
The secondary outcomes are shown in Table 3 . There were no significant differences in any measures between the groups at 30-day or 180-day follow-up.
| Patients who declined to participate
Of the 186 patients who declined to participate, 13 patients died within 30 days after discharge. Of the remaining 173 patients, 57 (33%) had an acute or planned readmission within 30 days after discharge.
| DISCUSSION
In this study, the pharmacist was able to identify and solve medication-related problems for the majority of the intervention patients.
The present study did not show any effect of pharmacist-led medicines management for older patients on medication-related readmissions or any secondary outcomes though. This is in contrast to other studies, where a comprehensive pharmacist-led intervention led to a reduction in medication-related readmissions 29, 30 and preventable medication-related visits. 35 One study also showed an effect on readmissions of all causes 36 whereas other studies did not. 29, [37] [38] [39] [40] There could be several reasons for not finding an effect on the primary outcome. In the calculation of the study size, a control rate for medication-related readmissions of 24% was used. However, in this study only 6% of the control patients had a medication-related readmission, indicating that the study was not powered to detect a FIGURE 1 Flow diagram of the participants in the study possible difference between the groups. This low rate is consistent with another study, 35 which found a rate of medication-related visits of 8% in the control group. As this study is older and from the US, it was not expected to reflect the Danish health care system as much as the two recent Swedish studies. 29, 30 Another reason could be selection of the healthiest older patients in the study due to the inclusion criteria. Also, the most morbid patients could have declined to participate. However, the frequency of readmissions of all causes was 33% in patients who declined to participate compared with 29% for the included patients, indicating that the latter is not the case.
This study is evaluated using hard endpoints. It is not known, if the intervention could have had an effect on other outcomes. It has been suggested that complex interventions like pharmacist-led medicines management should be evaluated with patient-related endpoints 41 as the purpose of the intervention is beneficial for the patient.
Only a reduced fraction of the interventions during inpatient stay and at discharge were delivered, making the intervention at admission the primary intervention in this study. However, a recent meta-analysis showed that comprehensive medication reconciliation at admission significantly reduced readmissions of all causes. 19 As the pharmacist was present on the acute admission unit, it was a challenge to find the physicians on other wards to orally present the recommendations from the medication review during hospital stay.
Therefore, only a few recommendations were discussed with a physician on other wards. This did not seem to affect the acceptance rate of the recommendations though, as this is slightly higher during inpatient
stay.
An automatic transfer of the pharmacist's medication report to the general practitioner was preferred, but this was not technically possible during the study period. From study start, the medical report on discharge was printed and given to the physician in charge of the patient. But due to logistical challenges, this was changed after inclusion of 1/3 of the patients. Thereafter, the medical report was written in the patient record instead. This made the intervention easier to deliver but could have limited the physician's focus on the intervention and the chance to orally discuss the report.
The pharmacist in the study only had a few years of clinical experience, which could have affected the results. In a Swedish study, the pharmacist was more experienced, 29 and this study showed a significant effect on medication-related readmissions.
The pharmacist was only present on weekdays, so the interventions were not offered during evenings, nights, and weekends. Only (12) 38 (19) 29 (15) Cardiology, n (%) 85 (43) 69 (35) 78 (39) General medicine, n (%) 92 (46) 93 (47) 93 (47) Medication administration before admission c Patient alone and/or private help, n (%) 149 (75) 158 (79) 157 (79) Assistance from home nurse, n (%) 36 (18) 32 (16) 29 ( one hospital and only one pharmacist participated in the study, which restricts the generalizability. On the other side, the reproducibility of the interventions was higher with only one pharmacist performing all interventions.
As the patients, staff, and pharmacist were not blinded to the group allocation, there was a risk of performance bias. It could have affected the acceptance rate but is unlikely to affect the primary or secondary outcomes. Detection bias with the subjective assessment of medication-related readmissions was sought prevented by blinding the reviewers to the allocation of the patients, although it could have affected the overall rate of medication-related readmissions.
The acute admission unit was unaccustomed to the presence of a clinical pharmacist. This meant that the physicians did not make use of the pharmacist for counselling in the beginning of the study period, but after a few months the staff was expecting the pharmacist to be present and started asking questions about medication. Also, the presence of the pharmacist could have affected the physicians' behavior with more focus on appropriate medication for all patients. In this way, the study contains a great risk of contamination bias, which is impossible to prevent when patients are randomized within the same ward. Outside a study setting, contamination bias (or educational bias as it also is called) could be most desirable. An Australian study
showed that the ward-based pharmacist often will be asked, when the staff seek advice about medications 42 which will improve the competences for both. But in a research setting, bias of this type could be overcome in future studies by cluster-randomization or other designs such as before-and-after study.
| CONCLUSIONS
In conclusion, this study showed that a clinical pharmacist can be used to identify and solve medication-related problems, but this study did not find any effect on the selected outcomes. The frequency of medication-related readmissions was low, leaving little room for improvement. Future research should consider other study designs or outcome measures.
